{
    "clinical_study": {
        "@rank": "63782", 
        "arm_group": {
            "arm_group_label": "rigosertib sodium", 
            "arm_group_type": "Experimental", 
            "description": "Rigosertib sodium will be administered as a 72-hr continuous intravenous infusion consisting of 3 consecutive doses of 1800 mg over 24 hours on Days 1, 2, and 3 of a 14-day cycle for the first 8 cycles and then on Days 1, 2, and 3 of a 28-day cycle for the following cycles."
        }, 
        "brief_summary": {
            "textblock": "This study will examine the effect intravenously administered rigosertib has on the\n      relationship between bone marrow blasts response and overall survival in  myelodysplastic\n      syndromes (MDS) patients who have 5-30% bone marrow blasts and who progressed on or after\n      treatment with azacitidine or decitabine."
        }, 
        "brief_title": "Efficacy and Safety of IV Rigosertib in MDS Patients With Excess Blasts Progressing After Azacitidine or Decitabine", 
        "completion_date": {
            "#text": "December 2015", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Myelodysplastic Syndromes", 
            "Refractory Anemia With Excess Blasts", 
            "Chronic Myelomonocytic Leukemia", 
            "Cytopenia"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Anemia", 
                "Anemia, Refractory", 
                "Anemia, Refractory, with Excess of Blasts", 
                "Leukemia", 
                "Leukemia, Myelomonocytic, Chronic", 
                "Myelodysplastic Syndromes", 
                "Preleukemia", 
                "Leukemia, Myelomonocytic, Acute"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Diagnosis of MDS confirmed within 6 weeks prior to Screening according to WHO\n             criteria or French-American-British (FAB) classification.\n\n          -  MDS classified as follows, according to WHO criteria and FAB classification:\n\n               -  RAEB-1 (5% to 9% BM blasts)\n\n               -  RAEB-2 (10% to 19% BM blasts)\n\n               -  CMML (10% to 20% BM blasts) and white blood cells (WBC) < 13,000/\u03bcL\n\n               -  RAEB-t (20% to 30% BM blasts), meeting the following criteria: WBC < 25,000/\u03bcL\n                  at study entry; or, Stable White Blood Cell (WBC) at least 4 weeks prior to\n                  Screening and not requiring intervention for WBC control with hydroxyurea,\n                  chemotherapy, or leukopheresis.\n\n          -  At least one cytopenia (Absolute Neutrophil Count (ANC) < 1800/\u03bcL or Platelet (PLT)\n             count < 100,000/\u03bcL or hemoglobin (Hgb) < 10 g/dL).\n\n          -  Progression (according to 2006 IWG criteria) at any time after initiation of\n             subcutaneous or intravenous azacitidine or decitabine treatment per labeling during\n             the past 2 years, defined as follows:\n\n               -  For patients with \u02c2 5% BMBL, \u2265 50% increase in BMBL to \u02c3 5% BMBL\n\n               -  For patients with 5-10% BMBL, \u2265 50% increase in BMBL to \u02c3 10% BMBL\n\n               -  For patients with 10-20% BMBL, \u2265 50% increase in BMBL to \u02c3 20% BMBL\n\n               -  For patients with 20-30% BMBL, \u2265 50% increase in BMBL to \u02c3 30% BMBL\n\n               -  Any of the following: \u2265 50% decrease from maximum remission/response levels in\n                  granulocytes or PLT; Decrease in Hgb concentration by \u2265 2 g/dL; or, Transfusion\n                  dependence, defined as administration of at least 4 RBC units in the past 8\n                  weeks before Screening (patients must have Hgb values \u02c2 9 g/dL prior to\n                  transfusion to be considered), in the absence of another explanation.\n\n          -  Has failed to respond to, relapsed following, not eligible, or opted not to\n             participate in bone marrow transplantation.\n\n          -  Off all other treatments for MDS for at least 4 weeks, except for azacitidine or\n             decitabine. Filgrastim (G-CSF) and erythropoietin are allowed before and during the\n             study as clinically indicated.\n\n          -  No medical need for induction chemotherapy.\n\n          -  Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1 or 2.\n\n          -  Willing to adhere to the prohibitions and restrictions specified in this protocol.\n\n          -  Patient must signed an informed consent form.\n\n        Exclusion Criteria:\n\n          -  Previous participation in a clinical study of IV or oral rigosertib.\n\n          -  Anemia due to factors other than MDS (including hemolysis or gastrointestinal [GI]\n             bleeding) unless stabilized for 1 week after RBC transfusion.\n\n          -  Any active malignancy within the past year, except basal cell or squamous cell skin\n             cancer or carcinoma in situ of the cervix or breast.\n\n          -  Uncontrolled intercurrent illness including.\n\n          -  Active infection not adequately responding to appropriate therapy.\n\n          -  Total bilirubin \u2265 1.5 mg/dL not related to hemolysis or Gilbert's disease.\n\n          -  ALT/AST \u2265 2.5 x upper limit of normal (ULN).\n\n          -  Serum creatinine \u2265 2.0 mg/dL.\n\n          -  Ascites requiring active medical management including paracentesis, or hyponatremia\n             (defined as serum sodium value of <130 mEq/L).\n\n          -  Female patients who are pregnant or lactating.\n\n          -  Patients who are unwilling to follow strict contraception requirements.\n\n          -  Female patients with reproductive potential who do not have a negative urine\n             beta-human chorionic gonadotropin (\u03b2HCG) pregnancy test at Screening.\n\n          -  Major surgery without full recovery or major surgery within 3 weeks of Baseline/Cycle\n             1 Day 1 visit.\n\n          -  Uncontrolled hypertension (defined as a systolic pressure \u2265160 mmHg and/or a\n             diastolic pressure \u2265 110 mmHg).\n\n          -  New onset seizures (within 3 months prior to Baseline) or poorly controlled seizures.\n\n          -  Any other concurrent investigational agent or chemotherapy, radiotherapy, or\n             immunotherapy.\n\n          -  Prior treatment with low-dose cytarabine during the past 2 years.\n\n          -  Investigational therapy within 4 weeks of Baseline/Day 1 visit.\n\n          -  Psychiatric illness or social situation that would limit the patient's ability to\n             tolerate and/or comply with study requirements."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "90", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "August 21, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01928537", 
            "org_study_id": "Onconova 04-24", 
            "secondary_id": "2013-001124-19"
        }, 
        "intervention": {
            "arm_group_label": "rigosertib sodium", 
            "intervention_name": "rigosertib sodium", 
            "intervention_type": "Drug", 
            "other_name": [
                "ON 01910.Na", 
                "SyB L-1101"
            ]
        }, 
        "intervention_browse": {
            "mesh_term": [
                "Azacitidine", 
                "Decitabine"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "International Working Group", 
            "azacitidine", 
            "decitabine"
        ], 
        "lastchanged_date": "May 28, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Stanford", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "94305"
                    }, 
                    "name": "Stanford University Cancer Center"
                }, 
                "investigator": {
                    "last_name": "Peter L. Greenberg, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Chicago", 
                        "country": "United States", 
                        "state": "Illinois", 
                        "zip": "60637"
                    }, 
                    "name": "University of Chicago Medicine"
                }, 
                "investigator": {
                    "last_name": "Lucy A. Godley, MD, PhD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Chicago", 
                        "country": "United States", 
                        "state": "Illinois", 
                        "zip": "60612"
                    }, 
                    "name": "Rush University Medical Center"
                }, 
                "investigator": {
                    "last_name": "Jamile Shammo, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Westwood", 
                        "country": "United States", 
                        "state": "Kansas", 
                        "zip": "66205"
                    }, 
                    "name": "University of Kansas Cancer Center and Medical Pavilion"
                }, 
                "investigator": {
                    "last_name": "Suman Kambhampati, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Baltimore", 
                        "country": "United States", 
                        "state": "Maryland", 
                        "zip": "21201"
                    }, 
                    "name": "Greenbaum Cancer Center University of Maryland"
                }, 
                "investigator": {
                    "last_name": "Maria Baer, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Boston", 
                        "country": "United States", 
                        "state": "Massachusetts", 
                        "zip": "02215"
                    }, 
                    "name": "Dana Farber Cancer Institute"
                }, 
                "investigator": {
                    "last_name": "David Steensma, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Rochester", 
                        "country": "United States", 
                        "state": "Minnesota", 
                        "zip": "55905"
                    }, 
                    "name": "Mayo Clinic"
                }, 
                "investigator": {
                    "last_name": "Aref Al-Kali, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Bronx", 
                        "country": "United States", 
                        "state": "New York", 
                        "zip": "10461"
                    }, 
                    "name": "Montefiore Medical Center"
                }, 
                "investigator": {
                    "last_name": "Amit Verma, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "New York", 
                        "country": "United States", 
                        "state": "New York", 
                        "zip": "10029"
                    }, 
                    "name": "Mount Sinai Medical Center"
                }, 
                "investigator": {
                    "last_name": "Lewis R. Silverman, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "New York", 
                        "country": "United States", 
                        "state": "New York", 
                        "zip": "10065"
                    }, 
                    "name": "New York Presbyterian Hospital-Weill Cornell Medical College"
                }, 
                "investigator": {
                    "last_name": "Gail Roboz, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "New York", 
                        "country": "United States", 
                        "state": "New York", 
                        "zip": "10032"
                    }, 
                    "name": "Columbia University Medical Center"
                }, 
                "investigator": {
                    "last_name": "Mark Heaney, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Dallas", 
                        "country": "United States", 
                        "state": "Texas", 
                        "zip": "75390"
                    }, 
                    "name": "University of Texas Southwestern Medical Center"
                }, 
                "investigator": {
                    "last_name": "Robert Collins, Jr., MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Adelaide", 
                        "country": "Australia", 
                        "state": "South Australia", 
                        "zip": "5000"
                    }, 
                    "name": "Royal Adelaide Hospital"
                }, 
                "investigator": {
                    "last_name": "Devendra Hiwase, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Clayton", 
                        "country": "Australia", 
                        "state": "Victoria", 
                        "zip": "3168"
                    }, 
                    "name": "Monash Health, Monash Medical Centre"
                }, 
                "investigator": {
                    "last_name": "Jake Shortt, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "East Melbourne", 
                        "country": "Australia", 
                        "state": "Victoria", 
                        "zip": "3002"
                    }, 
                    "name": "Peter MacCallum Cancer Center"
                }, 
                "investigator": {
                    "last_name": "John Seymour, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Parkville", 
                        "country": "Australia", 
                        "state": "Victoria", 
                        "zip": "3050"
                    }, 
                    "name": "Royal Melbourne Hospital"
                }, 
                "investigator": {
                    "last_name": "Jeff Szer, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Aarhus", 
                        "country": "Denmark", 
                        "state": "Jylland", 
                        "zip": "DK-8000"
                    }, 
                    "name": "Aarhus University Hospital"
                }, 
                "investigator": {
                    "last_name": "Mette Skov Holm, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Paris", 
                        "country": "France", 
                        "state": "IDF", 
                        "zip": "75475"
                    }, 
                    "name": "H\u00f4pital Saint-Louis, Service d'H\u00e9matologie"
                }, 
                "investigator": {
                    "last_name": "Pierre Fenaux, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Frankfurt", 
                        "country": "Germany", 
                        "state": "Hessen", 
                        "zip": "60590"
                    }, 
                    "name": "Universit\u00e4tsklinikum Frankfurt, Goethe Universit\u00e4t"
                }, 
                "investigator": {
                    "last_name": "Oliver G. Ottmann, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Dresden", 
                        "country": "Germany", 
                        "zip": "01062"
                    }, 
                    "name": "University Hospital Carl Guslav Carus"
                }, 
                "investigator": {
                    "last_name": "Uwe Platzbecker, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "D\u00fcsseldorf", 
                        "country": "Germany", 
                        "zip": "40479"
                    }, 
                    "name": "Marien Hospital, Onkologie"
                }, 
                "investigator": {
                    "last_name": "Aristoteles Giagounidis, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "K\u00f6ln", 
                        "country": "Germany", 
                        "zip": "50973"
                    }, 
                    "name": "Universit\u00e4tsklinikum K\u00f6ln Klinik I f\u00fcr Innere Medizin"
                }, 
                "investigator": {
                    "last_name": "Karl-Anton Kreuzer, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Firenze", 
                        "country": "Italy", 
                        "zip": "50134"
                    }, 
                    "name": "Azienda Ospedaliero-Universitaria Careggi"
                }, 
                "investigator": {
                    "last_name": "Valeria Santini, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Novara", 
                        "country": "Italy", 
                        "zip": "28100"
                    }, 
                    "name": "AOU Maggiore della Carit\u00e0, SCUD Ematologia"
                }, 
                "investigator": {
                    "last_name": "Gianluca Gaidano, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Rome", 
                        "country": "Italy", 
                        "zip": "00161"
                    }, 
                    "name": "Policlinico Umberto 1, Universita \"Sapienza\""
                }, 
                "investigator": {
                    "last_name": "Giuliana Alimena, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Gothenberg", 
                        "country": "Sweden", 
                        "state": "V\u00e4stra G\u00f6talandsregionen", 
                        "zip": "41345"
                    }, 
                    "name": "Sahlgrenska University Hospital"
                }, 
                "investigator": {
                    "last_name": "Hege Garelius, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": [
                "United States", 
                "Australia", 
                "Denmark", 
                "France", 
                "Germany", 
                "Italy", 
                "Sweden"
            ]
        }, 
        "number_of_arms": "1", 
        "official_title": "Phase IIIB, Open-label, Multi-Center Study of the Efficacy and Safety of Rigosertib Administered as 72-hour Continuous Intravenous Infusions in Patients With Myelodysplastic Syndrome With Excess Blasts Progressing On or After Azacitidine or Decitabine", 
        "overall_contact": {
            "email": "iwilhelm@onconova.us", 
            "last_name": "Isabellle Wilhelm, MD", 
            "phone": "609 281-7086"
        }, 
        "overall_official": {
            "affiliation": "Onconova Therapeutics, Inc.", 
            "last_name": "Francois E. Wilhelm, MD, PhD", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "September 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Bone marrow blast response is defined as bone marrow (BM) complete response, \u2265 50% BM blast decrease from pretreatment value, or stable BM response (no progression) according to the International Working Group (IWG) 2006 criteria. Overall survival is defined as the time from first study treatment to death from any cause. All patients will be followed until death and/or progression, even if they have discontinued treatment for whatever cause. Survival time of patients lost to follow-up will be censored at the time they were last known to be alive.", 
            "measure": "Relationship of  bone marrow blast response and overall survival.", 
            "safety_issue": "No", 
            "time_frame": "Up to 2 years."
        }, 
        "reference": [
            {
                "PMID": "22524974", 
                "citation": "Olnes MJ, Shenoy A, Weinstein B, Pfannes L, Loeliger K, Tucker Z, Tian X, Kwak M, Wilhelm F, Yong AS, Maric I, Maniar M, Scheinberg P, Groopman J, Young NS, Sloand EM. Directed therapy for patients with myelodysplastic syndromes (MDS) by suppression of cyclin D1 with ON 01910.Na. Leuk Res. 2012 Aug;36(8):982-9. doi: 10.1016/j.leukres.2012.04.002. Epub 2012 Apr 21."
            }, 
            {
                "PMID": "21924492", 
                "citation": "Seetharam M, Fan AC, Tran M, Xu L, Renschler JP, Felsher DW, Sridhar K, Wilhelm F, Greenberg PL. Treatment of higher risk myelodysplastic syndrome patients unresponsive to hypomethylating agents with ON 01910.Na. Leuk Res. 2012 Jan;36(1):98-103. doi: 10.1016/j.leukres.2011.08.022. Epub 2011 Sep 14."
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01928537"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Overall hematologic response (complete remission [CR], partial remission [PR], bone marrow complete response [BMCR], and stable disease [SD]) is defined according to 2006 International Working Group (IWG) response criteria.", 
                "measure": "Number of patients with overall hematologic response.", 
                "safety_issue": "No", 
                "time_frame": "Up to 2 years after study enrollment."
            }, 
            {
                "description": "Hematological improvement (erythroid response, platelet response and neutrophil response) is defined according to 2006 International Working Group (IWG) response criteria.", 
                "measure": "Number of patients with hematological improvement.", 
                "safety_issue": "No", 
                "time_frame": "Up to 2 years after study enrollment."
            }, 
            {
                "description": "Cytogenetic response is defined according to 2006 International Working Group (IWG) response criteria.", 
                "measure": "Number of patients with cytogenetic response.", 
                "safety_issue": "No", 
                "time_frame": "Up to 2 years after study enrollment."
            }, 
            {
                "description": "Progression-free survival is defined as time from date of first dose until date when progression is documented. Progression is defined according to 2006 International Working Group (IWG) response criteria.", 
                "measure": "Progression-free survival.", 
                "safety_issue": "No", 
                "time_frame": "Up to 2 years after study enrollment."
            }, 
            {
                "description": "Participants who progress to Acute Myeloid Leukemia (AML) during the study. AML is defined as an increase of at least 50% bone marrow blasts, and more than 20% bone marrow blasts for Refractory Anemia with Excess Blasts types 1 and 2 (RAEB-1 and RAEB-2) and Chronic Myelomonocytic Leukemia (CMML) patients and as an increase of at least 50% bone marrow blasts for Refractory Anemia with Excess Blasts in Transformation (RAEB-t) patients.", 
                "measure": "Number of patients who transition to Acute Myeloid Leukemia (AML)", 
                "safety_issue": "No", 
                "time_frame": "Up to 2 years after study enrollment."
            }, 
            {
                "description": "Change from baseline in responses in the European Organization for Research and Treatment of Cancer [EORTC] Quality of Life Questionnaire [QLQ]-C30 version 3. Questionnaire will be administered at baseline and at 4 week intervals.", 
                "measure": "Quality of Life Questionnaire", 
                "safety_issue": "No", 
                "time_frame": "Up to 2 years after study enrollment."
            }, 
            {
                "description": "Incidence of infections requiring treatment with intravenous antimicrobials and of bleeding episodes.", 
                "measure": "Infections.", 
                "safety_issue": "No", 
                "time_frame": "Up to 2 years after study enrollment."
            }, 
            {
                "description": "Concentration of rigosertib in plasma will be measured by a validated High Performance Liquid Chromatography (HPLC) method.", 
                "measure": "Concentration of rigosertib in plasma.", 
                "safety_issue": "No", 
                "time_frame": "Week 1 and week 3."
            }, 
            {
                "description": "Counts of patients who have adverse events (AEs).  Adverse events will be grouped by system organ class (SOC) and preferred term (PT) using the most recent version of the Medical Dictionary for Regulatory Activities (MedDRA), and will be summarized by worst grade according to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) version 4.0.", 
                "measure": "Safety.", 
                "safety_issue": "Yes", 
                "time_frame": "Study enrollment until 30 days after patient's last dose of rigosertib up to 2 years."
            }
        ], 
        "source": "Onconova Therapeutics, Inc.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Onconova Therapeutics, Inc.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "August 2013", 
        "study_design": "Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}